Cheplapharm Arzneimittel GmbH’s Agreement With Astellas Pharma Inc.

Freshfields Bruckhaus Deringer advised Cheplapharm Arzneimittel GmbH on the deal,

Cheplapharm Arzneimittel GmbH (‘Cheplapharm’) signed an agreement with Astellas Pharma Inc., a Japan based pharmaceutical company, to purchase products rights for five products in certain countries (Europe, Russia, Commonwealth of Independent States, Asia) through an asset deal.

Cheplapharm is a pharmaceutical company headquartered in Greifswald, Germany, offering branded and niche products in more than 120 countries worldwide. It has been one of the fastest-growing pharmaceutical companies in Europe.

Freshfields advised on all legal cross-border aspects of the asset purchase agreement. The Freshfields core team comprised partners Jochen Dieselhorst (Picture) and Lars Meyer as well as Johannes Kater, Elisabeth Wulf and Christoph Becherer (all Corporate); partner Christian Ruoff and Andrea Strackerjan advised on tax topics.

Cheplapharm’s inhouse legal team included Legal Counsel Dr. Jan Klumb and Junior Legal Counsel Anees Ahmed.

Involved fees earner: Christoph Becherer – Freshfields Bruckhaus Deringer LLP; Jochen Dieselhorst – Freshfields Bruckhaus Deringer LLP; Johannes Kater – Freshfields Bruckhaus Deringer LLP; Lars Meyer – Freshfields Bruckhaus Deringer LLP; Christian Ruoff – Freshfields Bruckhaus Deringer LLP; Andrea Strackerjan – Freshfields Bruckhaus Deringer LLP; Elisabeth Wulf – Freshfields Bruckhaus Deringer LLP;

Law Firms: Freshfields Bruckhaus Deringer LLP;

Clients: Cheplapharm Arzneimittel GmbH;

Author: Federica Tiefenthaler